Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Spruce Power Fourth Quarter 2025 Earnings Call - Breakout year: margins widened, cash flow turned positive, refinancing now the critical next step
Spruce closed 2025 with a genuine operational inflection. Q4 revenue rose to about $24 million, operating EBITDA topped $17 million, and full year operating EBITDA hit $80.1 million, a 49% jump versus...
- Q4 2025 revenue approximately $24 million, up 19% year over year; full year revenue up 36% versus 2024.
- Q4 operating EBITDA exceeded $17 million; full year operating EBITDA was $80.1 million, a 49% increase year over year.
- Adjusted cash flow from operations swung to $5.1 million in Q4, versus -$4.1 million in Q4 2024, signaling improved cash generation.
- +11 more takeaways
INmune Bio Q4 2025 Earnings Call - CORDStrom on track for U.K. MAA mid-2026, BLA targeted end-2026
INmune Bio presented a bifurcated quarter: a regulatory push for CORDStrom while reconciling mixed readouts from its Alzheimer program. Management says CORDStrom has reproducible, pooled-donor manufac...
- CORDStrom is the companys lead value driver, positioned for registration in RDEB with an MAA planned in the U.K. by mid-summer 2026.
- Following the U.K. filing, INmune plans to submit an MAA to the EMA and a BLA to the FDA by the end of 2026, with regulatory feedback or approvals expected in 2027.
- Manufacturing claim: CORDStrom uses pooled mesenchymal stromal cell banks from four or more donors, delivering batch-to-batch consistency and reproducibility for commercial supply.
- +11 more takeaways
Intellinetics Q4 2025 Earnings Call - SaaS growth cushions services slump, investments weigh on profitability
Intellinetics closed 2025 with clear progress in SaaS, but not yet with a clean bill of health. SaaS revenue grew double digits for the year and was up 8.4% in Q4, improving margins and offsetting a m...
- CEO change: Alison Forsythe became CEO in mid-February and focused immediately on operations, go-to-market, and execution improvements.
- Q4 revenue: Total revenue for Q4 2025 was $4.3 million, up 1% year over year.
- SaaS growth: SaaS and hosting revenue rose 8.4% year over year in Q4 to $1.6 million; SaaS grew 11.1% for the full year.
- +11 more takeaways
Fermi America Q4 & FY 2025 Earnings Call - Matador substantially built, now hostage to tenant leases and project financing
Fermi America is no longer a paper promise, it is a construction site. Management reports roughly $570 million deployed into Project Matador, $935 million of PP&E in construction in progress, and key ...
- Project Matador has moved from formation to heavy construction: ~$570 million of investor capital deployed into Matador (construction in progress), PP&E of ~$935 million as of 12/31/2025.
- Company is pre-revenue. Net loss for the fiscal period was $486 million, with ~$445 million non-cash items; operating cash use was $34 million for the year.
- Cash and liquidity: $409 million cash on 12/31/2025, plus ~ $1 billion of financing proceeds in 2025 and subsequent equipment facilities (MUFG $500m turbine warehouse, Keystone $120m expandable, Yellowstone $165m) that, with cash, provide at least 12 months of liquidity.
- +11 more takeaways
PAVmed Fourth Quarter 2025 Earnings Call - Capital Structure Cleaned, Lucid Momentum and Medtech Relaunch Set the Agenda
PAVmed says the long, painful chapter of toxic convertibles is over. A February recapitalization and financing left the company with a clean cap table, roughly $30 million of new equity, $15 million o...
- Recapitalization completed in February removed legacy toxic convertible securities and produced a clean cap table, converting $30 million of short-term preferred into common and adding $15 million of 3-year, 15% interest-only debt.
- PAVmed now shows pro forma total assets north of $100 million after the financing, with $15 million of long-term debt on the balance sheet and a $30 million warrant package tied to the Series D.
- PAVmed remains the single largest shareholder of Lucid Diagnostics, holding roughly 31 million shares (equity method investment approx. $34 million) and about an 18% ownership stake, with ~25% voting interest.
- +16 more takeaways
Bicara Therapeutics Q4 2025 Earnings Call - Breakthrough Therapy Designation and 1,500 mg Weekly Chosen as Pivotal Dose with Mid-2027 Interim for Accelerated Approval
Bicara used its first quarterly call to tighten the story: ficerafusp alfa is now positioned as a potential best-in-class, chemo-sparing therapy for frontline recurrent/metastatic HPV-negative head an...
- FDA granted Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab for first-line metastatic or unresectable HPV-negative head and neck squamous cell carcinoma.
- Company selected 1,500 mg weekly as the optimal biological dose and has advanced FORTIFY-HN01 into the phase III portion with 2-to-1 randomization versus pembrolizumab monotherapy.
- Planned interim analysis for FORTIFY-HN01 is expected mid-2027, focused on overall response rate, durability of response and qualitative overall survival, reviewed by an IDMC while management remains blinded.
- +12 more takeaways
Rezolve AI 2H & FY2025 Earnings Call - Exit ARR $232.8M, Upgraded 2026 Revenue Guidance to $360M
Rezolve AI says 2025 was the inflection year. The company exited December with $19.4 million in MRR, implying a $232.8 million ARR, reported $46.8 million in full-year revenue, and claims the second h...
- Exit December MRR was $19.4 million, implying an exit ARR of $232.8 million (audited figure disclosed in the 20-F).
- Full-year 2025 GAAP revenue was $46.8 million, with a 543% acceleration in the second half as customers moved into production.
- Management upgraded 2026 GAAP revenue guidance to $360 million, and is targeting a $500 million ARR at year-end 2026.
- +12 more takeaways
Nano Labs Ltd Second Half 2025 Earnings Call - BNB reserves and crypto income drive profit while cash and inventory hits raise questions
Nano Labs frames H2 2025 as a strategic inflection: it built a large BNB reserve, booked hefty crypto-related other income, and pivoted toward AI agent hardware with the March 2026 launch of the iPoll...
- As of December 31, 2025 the company reported holding 126,662 BNB and 3,338 BNB as receivable collateral, naming BNB a core element of its strategic crypto reserve.
- Management completed two financing rounds in 2025 to support strategic transformation, expanded crypto reserves, and new business directions.
- Company announced a share repurchase program in October 2025 of up to $25 million, and has begun implementing it gradually.
- +12 more takeaways
Sigma Lithium Q4 2025 Earnings Call - Cash machine as dry-stack fines fund debt paydown, Plant Two set for early 2027 commissioning
Sigma spent 2025 turning operational pain into cash. Management monetized dry-stack tailings by reprocessing lithium fines, generating meaningful cash sales that funded a sizable debt paydown and kept...
- New revenue line, reprocessing dry-stack tailings into high-purity lithium fines, materially boosted cash flow; Q1 2026 fines sales included roughly $30 million.
- Sigma signed about $146 million of offtake prepayments in 2025: $96 million for 70,000 t (2026 deliveries) and a $50 million 3-year typical offtake for 40,000 t/year (120,000 t total).
- Management repaid roughly 60% of short-term debt and about 35% of total debt year over year, without raising new equity.
- +12 more takeaways
Neumora Therapeutics Q4 2025 Earnings Call - Catalyst-rich pipeline: navacaprant readouts in Q2 2026, NMRA-215 delayed to Q1 2027 after rat tox audit
Neumora positions itself for a busy 12 months, with two phase III readouts for navacaprant expected in Q2 2026, multiple phase I/II data points across M4 PAMs and NMRA-511 through 2026, and a planned ...
- Neumora expects multiple near-term clinical catalysts: KOASTAL-2/KOASTAL-3 top-line in Q2 2026, NMRA-511 MAD extension readout H2 2026, NMRA-898 MAD data H2 2026, and NMRA-511 phase II initiation in Q1 2027.
- KOASTAL-2 and KOASTAL-3 (navacaprant, KOR antagonist for MDD) are fully enrolled with >400 patients each; a joint top-line readout will include individual study results plus pre-specified post-pause pooled analyses.
- Following protocol optimizations after KOASTAL-1, Neumora implemented SAFER procedures, enhanced screening to exclude professional patients, and pared sites; screen-fail rates rose ~10% versus KOASTAL-1, which management views as higher quality enrollment.
- +12 more takeaways